London-listed Oncimmune (AIM:ONC ) said its data from one of its studies will be featured at a prestigious international cancer research conference later this month.
The global immunodiagnostics group said the conference will feature findings from profiling tumour associated antibodies in melanoma patients receiving immune checkpoint inhibitors.
The data will be showcased at the upcoming American Society of Clinical Oncology 2020 ("ASCO") Virtual Scientific Programme, which will take place from May 29 to May 31, 2020.
Data will be reviewed assessing samples from patients receiving either Pembrolizumab, Ipilimumab, Nivolumab monotherapy, or combination therapy of Ipilimumab and Nivolumab.
All treatments under review have been previously analysed on Oncimmune's proprietary biomarker discovery engine, SeroTag®, this morning’s statement said.
Shares in Oncimmune Holdings were trading 1.84% higher at 83p on Thursday.
Specifically, the previously reviewed data has identified that autoantibodies have a role in predicting clinical outcomes or immune-related adverse events (irAEs).
Oncimmune said this will be the first time that the clinical utility of autoantibodies will have been presented at this prestigious international cancer research conference.
Adam M Hill, CEO of Oncimmune, said the study highlights the important role autoantibodies play in identifying patients likely to suffer immune-related adverse events in response to cancer immunotherapy - this time in patients suffering from melanoma.
“Importantly, the study also reinforces the evidence base underpinning the utility of tumour related antibodies in predicting clinical responses to commonly used first-line treatment immunotherapies,” he said.
He added, “This exciting study demonstrates the strides we have made in unlocking the potential of our autoantibody platform to improve patient outcomes."
The group announced earlier this week an antigen targeting deal which will see SeroTag support drug development alongside an unnamed leading US biopharmaceutical company.
Follow News & Updates from Oncimmune Holdings here: